Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.

Molecular cancer therapeutics - 1 Aug 2016

Stottrup Casey, Tsang Tiffany, Chin Y Rebecca

Abstract excerpt

Acquired resistance to molecular targeted therapy represents a major challenge for the effective treatment of cancer. Hyperactivation of the PI3K/AKT pathway is frequently observed in virtually all human malignancies, and numerous PI3K and AKT inhibitors are currently under clinical evaluation. However, mechanisms of acquired resistance to AKT inhibitors have yet to be described. Here, we use a breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Survival
Share to Cellular Reprogramming

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Gene Knockdown Techniques

Share to Heterocyclic Compounds, 3-Ring

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 27297869
DOI: 10.1158/1535-7163.MCT-15-0748
PMCID: PMC4975650

Genes

AKT3
AKT1
AKT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.PMID 27297869Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read ↗

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.Semantic proximity Read ↗

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerSemantic proximity Read ↗

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsSemantic proximity Read ↗

HER2/PI3K/AKT pathway in HER2-positive breast cancer: A reviewSemantic proximity Read ↗

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsSemantic proximity Read ↗

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.Semantic proximity Read ↗

Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasisSemantic proximity Read ↗

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Semantic proximity Read ↗

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.